Renal replacement therapies in pediatric intensive care patients: Experiences of one center in Turkey

BACKGROUND: Despite constant improvements in caring for critically ill neonates and infants with congenital cardiac disease, sepsis, bone marrow and solid organ transplantation, acute renal failure (ARF) is an important problem in these children. ARF, severe fluid overload and inborn errors of metabolism are some of the indications for acute dialysis in infants and children. METHODS: The authors had retrospectively evaluated the medical records of Pediatric Intensive Care Unit, Ankara University School of Medicine, Ankara, Turkey patients who had required acute renal replacement therapy between the dates of January 2002 to February 2005. RESULTS: Medical records of 332 patients were reviewed. Acute renal replacement therapy was performed in 21 patients (6.3%; mean age, 9.6 +/- 7.4 years). Dialysis modalities were peritoneal dialysis in 15 patients (71.4%; mean age, 3.9 +/- 5.6 years) and hemodialysis in six patients (28.6%; mean age, 12.1 +/- 3.2 years). A total of 90% of patients had severe systemic disease leading to ARF. A total of 95% of patients had multiple organ dysfunction syndrome. The most common cause of ARF was refractory shock. At the beginning of renal replacement therapy, 10 patients were anuric, nine patients had volume overload, seven patients had decompensated metabolic acidosis and nine patients had hypotension. The average dialysis period was 4.7 +/- 6.4 days. Mortality rate was 66.7%. Eight patients recovered from ARF and chronic renal failure had developed in one patient. CONCLUSION: In the Pediatric Intensive Care Unit, ARF is frequently seen together with multiple organ dysfunction syndrome and the mortality rate is high. Both peritoneal dialysis and hemodialysis are important renal replacement treatment modalities in patients with ARF. The age and hemodynamic status of the patients are important when choosing treatment modality; generally peritoneal dialysis is preferred in infants and toddler, while hemodialysis is preferred in older children.     

1,25-dihydroxycholecalciferol in renal osteodystrophy. Epiphysiolysis--anticonvulsant therapy

Three children with azotaemic renal osteodystrophy were treated with 1,25-dihydroxycholecalciferol (1,25(OH)2D3). All showed clinical, biochemical, and radiological improvement within 6 months of starting treatment. There were no complications. The dose of 1,25(OH)2D3 required was 0-5 microgram per day for 2 children aged 22 and 30 months, and 2 microgram per day for a 15-year-old boy. 2 of the patients were receiving phenobarbitone and phenytoin and in one of them prior treatment with dihydrotachysterol 0-5 mg daily and 6 microgram 1alpha-hydroxycholecalciferol (1alphaOHD3) daily had failed to induce improvement. In one patient, in whom serial iliac bone samples were available, 2 microgram 1,25(OH)2D3 resulted in histological improvement in previously severe osteomalacia. 1,25(OH)2D3 appears to be an effective and safe drug in the treatment of uraemic osteodystrophy.     

2种用药方案治疗慢性丙型肝炎的药物经济学评价

目的:评价2种用药方案治疗慢性丙型肝炎(CHC)的经济学效果。方法:185例CHC患者按照治疗方案的不同分为长效组(聚乙二醇干扰素α-2a联合利巴韦林)与普通组(普通干扰素α-2a联合利巴韦林),针对不同基因型分别采用最小成本分析法和成本-效果分析法进行研究,效果指标采用持续病毒学应答率(SVR),成本指标采用直接医疗服务成本。结果:对于基因2型、3型的CHC患者,长效组与普通组的SVR分别为76.5%、63.5%(P>0.05),治疗成本分别为30235.20、36950.40元(P<0.05);对于基因1型、未分型的CHC患者,长效组与普通组的SVR分别为52.9%、25.8%(P<0.05),成本-效果比分别为114310.77、143218.60,长效组相对于普通组的增量成本-效果比为86789.67。结论:从药物经济学角度看,聚乙二醇干扰素α-2a联合利巴韦林治疗CHC优于普通干扰素α-2a联合利巴韦林方案。     

Ad-GFP修饰MSCs静脉移植在严重烫伤延迟复苏大鼠体内的定向迁移

目的:观察携带目的基因的大鼠骨髓间充质干细胞(mesenchymal stem cells ,MSCs) 静脉移植在严重烫伤延迟复苏损伤体内的分布.方法:分离培养MSCs,用Ad-GFP转染MSCs,25只Wistar大鼠随机分为延迟复苏组(A组,10只)、即时复苏组(B组,10只)、假伤组(C组,5只).A、B两组大鼠背部造成Ⅲ度30%烫伤,制备A组为延迟复苏模型,B组为即时复苏模型,同时制备C组为假伤模型,经股静脉移植转染Ad-GFP 48 h后的MSCs.24 h,7 d后取小肠、肝脏、肾脏、烫伤皮肤创缘等组织,快速冰冻切片,荧光显微镜下观察在体内的分布.结果:MSCs 体外分离培养扩增5代,细胞数可达(1～2)×1011个,具有多态性和贴壁生长特性,MOI=100时,Ad-GFP转染MSCs效率可达86.4%.经股静脉移植24 h,在延迟复苏组烫伤皮肤组织创缘,小肠黏膜广泛可见绿色荧光,而在肝、肺等器官少见,即时复苏组荧光以烫伤皮肤创缘分布为主,小肠黏膜较少,假伤组中绿色荧光分布以肝脏为主.延迟复苏组小肠荧光强度明显强于即时复苏组和假伤组(P《0.05),而延迟和即时复苏组皮肤创缘荧光强度又强于假伤组(P《0.05).结论:导入目的基因可能不会改变MSCs归巢特性,并将为后续启动基因治疗烧伤延迟复苏后的损伤研究提供参考.     

Are vitamin B12 and folate deficiency clinically important after roux-en-Y gastric bypass?

Although iron, vltamm B₁₂, and folate deficiency have been well documented after gastric bypass operations performed for morbid obesity, there is surprisingly little information on either the natural course or the treatment of these deficiencies in Roux-en-Y gastric bypass (RYGB) patients Durmg a l0-year period, a complete blood count and serum levels of iron, total iron-binding capacity, vltamin B₁₂, and folate were obtained in 348 patients preoperatively and postoperatively at 6-month intervals for the first 2 years, then annually thereafter The principal objectives of this study were to determine how readily patients who developed metabolic deficiencies after Roux-en-Y gastric bypass responded to postoperative supplements of the deficient micronutrient and to learn whether the risk of developmg these deficiencies decreases over time Hemoglobin and hematocrit levels were slgnificantly decreased at all postoperative intervals in comparison to preoperative values Moreover, at each successive interval through 5 years, hemoglobin and hematocrit were decreased signifiantly compared to the preceding interval Folate levels were significantly increased compared to preoperative levels at all time intervals Iron and vltamin B₁₂ levels were lower than preoperative measurements and remained relatively stable postoperatively Half of the low hemoglobin levels were not associated with iron deficiency Taking multivltamin supplements resulted in a lower incidence of folate deficiency but did not prevent iron or vitamin B₁₂ deficiency Oral supplementation of iron and vitamin B₁₂ corrected defiaencies in 43% and 81% of cases, respectively Folate deficiency was almost always corrected with multivitamins alone No patient had symptoms that could be attributed to either vitamin B₁₂ or folate deficiency Conversely, many patients had symptoms of iron deficiency and anenua Lack of symptoms of vitamin B₁₂ and folate deficiency suggests that these deficiencies are not clinically important after RYGB Conversely, iron deficiency and anemia are potentially serious problems after RYGB, particularly in younger women Hence we recommend prophylactic oral iron supplements to premenopausal women who undergo RYGB     

BAG-1、p53在非小细胞肺癌中的表达及其与含铂方案化疗敏感性的关系

目的检测非小细胞肺癌（NSCLC）术后患者BAG-1、p53的表达,回顾分析其与患者临床特征及含铂方案化疗敏感性的关系,进一步探讨NSCLC的铂类耐药机制。方法应用免疫组织化学的方法检测125例NSCLC术后石蜡标本中BAG-1、p53的表达,随访后进行生存预后分析。结果BAG-1、p53在NSCLC组织中存在高表达（阳性率分别为64．8％和46．7％）;BAG-1阳性、p53阴性患者具有生存优势（P〈0．05）;BAG-1、p53表达阴性患者更能在含铂方案化疗后受益（P〈0．05）。结论BAG-1、p53与铂类药物化疗敏感性相关,可能成为新型的临床预后指标,有助于肿瘤个体化治疗方案的选择。     

多层螺旋CT双期增强扫描结合仿真内镜成像在膀胱癌术前分期中的诊断价值

目的 探讨多层螺旋CT双期增强扫描结合仿真内镜成像在膀胱癌术前分期中的诊断价值.方法 经纤维膀胱镜或手术病理证实为膀胱癌患者75例.对患者术前螺旋CT双期增强扫描图像和仿真内镜图像进行分析,比较多层螺旋CT分期与病理分期的准确率.结果 75例患者共发现病灶94个.螺旋CT分期:T1 26例、T2a 27例、T2b 13例、T3 12例、T4 16例;病理分期:pT1 28例、pT2a 24例、pT2b 14例、pT3 12例、pT4 16例.螺旋CT双期增强扫描诊断膀胱癌准确率为89.4%(84/94);腔内息肉样病变,仿真内镜诊断敏感性96.6%(84/87);膀胱壁无蒂隆起性病变诊断敏感性为90.9%(10/11).螺旋CT双期增强扫描结合仿真内镜诊断膀胱癌分期准确率为94.5%(91/94),当肿瘤局限于膀胱壁内(≤T2b)时,诊断准确率为91.2%(51/56);肿瘤侵犯膀胱壁外结构时(≥T3),诊断准确率达100.0%(28/28).结论 多层螺旋CT双期增强扫描结合仿真内镜成像对膀胱癌术前临床分期具有重要价值.     

FRAX在中国绝经后女性人群骨折风险预测中的适用性评价

目的评价世界卫生组织发布的骨折风险预测工具(FRAX)对中国绝经后女性人群的适用性,探索有、无股骨颈骨密度(BMD)对FRAX预测结果的影响。方法对2314名绝经后中国女性进行回顾性队列分析。采集所有入选者FRAX预测工具中所包含的各危险因素资料,将包括股骨颈BMDT值等数据输入FRAX,计算10年骨折风险。从所有危险因素数据中得出针对中国绝经后女性骨折风险预测的回归方程,将该方程得出的骨折风险值与FRAX预测值相比较。对有无BMD情况下的FRAX预测值进行比较。结果除吸烟和饮酒外,FRAX预测风险与各危险因素间均具有统计学意义,既往骨折史是最重要的危险因素。骨质疏松引起的主要骨折概率(临床性椎体、髋部、肱骨和前臂骨折)和髋部骨折的概率均随着股骨颈BMD的下降而升高。根据中国绝经后女性骨折风险预测回归方程计算的髋部骨折风险概率与FRAX预测结果一致,有无BMD情况下的FRAX预测结果差异无统计学意义。结论 FRAX可用于中国绝经后女性人群骨折风险预测,无BMD情况下的FRAX预测结果同样可靠。     

开角型青光眼静态视野黄斑光阈值的改变

目的 观察开角型青光眼患者静态视野黄斑光阈值改变，探讨测定黄斑光阈值与青光眼早期视功能损害的关系。方法 采用Dicon全自动静态阈值视野计，分别对89例开角型青光眼(早期青光眼45例，中晚期青光眼44例)和正常人40名黄斑光阈值进行测定。结果 早期青光眼患者黄斑光阈值明显高于正常对照组，中晚期患者高于早期患者，3组数据差异有统计学意义。结论 测定黄斑光阈值对于青光眼早期视功能损害的评价有一定的临床意义。